A Phase 3 Randomized Double-blind Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with MIBC (KEYNOTE-992)

Brief description of study

The purpose of the study is to determine the safety and efficacy of Pembrolizumab (MK-3475) and Chemoradiotherapy (CRT) for people who have muscle-invasive bladder cancer. We want to know if Pembrolizumab (MK-3475) and Chemoradiotherapy (CRT) is better than CRT alone. You will be randomized to either treatment.


Clinical Study Identifier: s19-01027
ClinicalTrials.gov Identifier: NCT04241185
Principal Investigator: Scot Niglio.
Other Investigators: Maya Dimitrova, James S Wysock, Wei Phin Tan, Anthony Corcoran, Casey E Chambers, Victor Ricardo Adorno Febles, Mary K O'Keeffe, Minas Platon Economides, Todd J Carpenter, Peter B. Schiff, Moses M Tam, William C Huang, Michael J. Zelefsky, Hank Ng, David R. Wise.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.